



# ARROWGARD<sup>+</sup> BLUE PLUS<sup>®</sup>

## Central Venous Catheters

*AGB<sup>+</sup> symbol identifies the ARROWgard Blue PLUS technology*

*Silver sulfadiazine and chlorhexidine impregnated on outside, chlorhexidine inside, including extension lines and hubs*

*The new generation ARROWgard Blue PLUS enhances the performance of the clinically proven ARROWgard Blue CVC range*

**Description**  
Triple Lumen 7 Fr. x 8" (20 cm)  
ARROWgard Blue Plus CVC  
(available in 2, 3 and 4 lumens)

### CHLORHEXIDINE/SILVER SULFADIAZINE RECOMMENDED BY THE CDC

Protecting patients from infection has always been at the heart of the healthcare worker's mission. And it's only going to become more important. Consider the well-documented rise in nosocomial infections – and responses like the Institute for Healthcare Improvement's 5 Million Lives Campaign.

Antimicrobial catheters can play an integral role in protecting patients from risk. But before physicians and nurses choose one, they need proof that it can reduce the risk of infection and lower the costs associated with treatment and hospitalisation. That's exactly what they get with ARROWgard Blue PLUS (AGB<sup>+</sup>) catheters.

### EFFICACY VERIFIED BY MORE THAN 30 STUDIES

ARROWgard is a patented combination of silver sulfadiazine and chlorhexidine impregnated into the catheter surface. Chlorhexidine/silver sulfadiazine is recommended by the Centers for Disease Control (CDC) as a 1B recommendation for the prevention of catheter-related infection.<sup>1</sup>

ARROWgard's ability to reduce infection, save lives and reduce costs has been supported by more than 30 studies.<sup>2</sup> No other company's catheters have such a strong track record. Or such broad-spectrum activity.

For example, ARROWgard reduces bacterial colonisation of the catheter by 60 per cent and catheter-related blood-stream infection by an even greater 80 per cent.<sup>3</sup> And it's effective against a wide array of gram-positive bacteria, including *S. epidermidis*, MRSA and *S. aureus*; gram-negative bacteria, including *Enterococci* and *Pseudomonas* strains; and fungi, including *C. albicans*.<sup>2</sup>

## SAVINGS BY RATE OF INFECTION

|                                      | UNPROTECTED CATHETER. | ARROWGÅRD-IMPREGNATED CATHETER  |
|--------------------------------------|-----------------------|---------------------------------|
| Catheters used per year              | 500                   | 500                             |
| Total infections                     | 15                    | 3 (80 % reduction) <sup>3</sup> |
| Cost per infection                   | \$34,508              | \$34,508                        |
| Total infection cost                 | \$517,620             | \$103,524                       |
| Cost per catheter                    | \$60                  | \$73                            |
| Total catheters + infections         | \$547,620             | \$140,024                       |
| <b>Savings using AGB<sup>+</sup></b> |                       | <b>\$407,596</b>                |

## SAVINGS BY 1,000 CATHETER DAYS

|                                      | UNPROTECTED CATHETER. | ARROWGÅRD-IMPREGNATED CATHETER     |
|--------------------------------------|-----------------------|------------------------------------|
| Catheters used per year              | 500                   | 500                                |
| Infections/1,000 catheter days       | 4.4                   | 0.88 (80 % reduction) <sup>4</sup> |
| Cost per infection                   | \$34,508              | \$34,508                           |
| Total infection cost                 | \$546,240             | \$109,248                          |
| Cost per catheter                    | \$60                  | \$73                               |
| Total catheters + infections         | \$576,240             | \$145,748                          |
| <b>Savings using AGB<sup>+</sup></b> |                       | <b>\$430,492</b>                   |

## PROTECTION OUTSIDE AND IN: AGB<sup>+</sup>

Our next-generation ARROWgÅrd Blue PLUS catheters give you proven infection-fighting ability both outside and in (including extension lines and hubs). Better still, the concentration of chlorhexidine on the outside surfaces is three times higher than on our original ARROWgÅrd catheters. So chlorhexidine and silver sulfadiazine continuously prep the subcutaneous catheter tract and kill organisms in harder-to-reach areas, away from the influence of skin preps and external dressings.

## REDUCING INFECTIONS CUTS COSTS

Catheter-related bloodstream infections (CRBSIs) do happen; even highly focused programmes in hospitals report low CRBSI rates between 2 and 5 per cent. No matter how infrequent they may be, CRBSIs are expensive: Treating a single incident can total \$56,000 or more due to pharmacy charges, catheter changes, additional days in the ICU, lab tests and extended hospital stays.<sup>4</sup>

By taking advantage of ARROWgÅrd's proven infection-prevention capabilities, your institution can reduce those costs.

For more information on reducing risk for patients and healthcare workers, visit [FirstDoNoHarm.com](http://FirstDoNoHarm.com).

### DISTRIBUTED BY:

TELEFLEX MEDICAL HEADQUARTER EMEA, IRELAND · IDA Business & Technology Park · Athlone · Co Westmeath

Tel. +353 (0)9 06 46 08 00 · Fax +353 (0)14 37 07 73 · [orders.intl@teleflex.com](mailto:orders.intl@teleflex.com)

UNITED KINGDOM Tel. +44 (0)14 94 53 27 61 · [info.uk@teleflex.com](mailto:info.uk@teleflex.com)

SOUTH AFRICA Tel. +27 (0)11 807 4887 · [assist.africa@teleflex.com](mailto:assist.africa@teleflex.com)

[WWW.TELEFLEX.COM](http://WWW.TELEFLEX.COM)

94 10 65 - 00 00 01 · REV A · 08 11 02 · All data current at time of printing. Subject to technical changes without further notice.

## REFERENCES:

- 1 O'Grady, N.P., Alexander, M., Dellinger, E.P., Gerberding, J.L., Heard, S.O., Maki, D.G., Masur, H., McCormick, R.D., Mermel, L.A., Pearson, M.L., Raad, I.I., Randolph, A., Weinstein, R.A. "Guidelines for the Prevention of Intravascular Catheter-Related Infections." The Centers for Disease Control, August 9, 2002, Vol. 51, No. RR10, pp. 7-8.
- 2 References include but are not limited to Maki 1997, Sampath 1995 and Bach 1994.
- 3 Maki, D.G., Stolz, S.M., Wheeler, S., Mermel, L.A. "Prevention of Central Venous Catheter-Related Bloodstream Infection With an Antiseptic-Impregnated Catheter: A Randomized, Controlled Trial." *Annals of Internal Medicine*, August 15, 1997, Vol. 127, Issue 4, pp. 257-266.
- 4 O'Grady et al. "Guidelines for the Prevention of Intravascular Catheter-Related Infections." *Infection Control Hospital Epidemiology*, Dec. 2002, Vol. 23, Issue 12, pp. 759-69.

Full bibliography available upon request.

## PATENTS:

ARROWgÅrd®/

ARROWgÅrd® Blue PLUS®:

U.S. Patent Nos. 6,706,024 and 6,872,195.

## CAUTION:

Contents of unopened, undamaged package are sterile. Disposable. Refer to package insert for current warnings, indications, contraindications, precautions and instructions for use.

For additional reference information contact Arrow International, Inc. This product is CE marked according to the Medical Devices Directive 93/42/EEC